CRSP

Over the past six months, CRISPR Therapeutics AG's stock has fluctuated, with a 1-year change of -6.4% as of September 18, 2026, and a 52-week range of $44.12 to $78.48. Key events include Q1 2026 earnings with an EPS of -1.280 USD and Q2 2026 earnings reporting $10.181 million in GAAP total revenue and a GAAP net loss of $(91.154) million. The company presented positive Phase 1a data for CTX310 at the ESC Congress 2026 and announced participation in the Morgan Stanley 24th Annual Global Healthcare Conference. Regulatory approvals for CASGEVY in children with SCD or TDT by the FDA and in 39 other countries significantly impacted the stock. Pipeline expansion included the initiation of Phase 1 clinical trials for CTX340 and CTX460. Financing activities included net proceeds of $585.4 million from convertible senior notes in March 2026, contributing to $2,364.4 million in cash, cash equivalents, and marketable securities as of June 30, 2026. The stock experienced a largest daily move of +12.9% on August 19, 2026, and a 7-day share price return of 9.36% leading up to September 21, 2026, despite a 1-month return down 4.94%.